When AI reads between the cells

#AI #BreastCancer #BreastCancerAwareness  


Breast cancer is a heterogeneous disease, and some aggressive forms require neoadjuvant therapy (NAT) before surgery. This treatment aims to reduce tumor size, improve surgical resection, and assess tumor sensitivity to the therapeutic agents used. However, the response to NAT varies greatly from one patient to another. Moreover, there is currently no reliable tool in clinical practice to predict its effectiveness early. The limitations of current approaches include inter-observer variability in pathology, subjectivity of interpretation, and the inability to extract complex morphological features visible only under advanced analysis.